# FAERS Data Analysis Report

## Executive Summary

This report documents the statistical analysis of FDA Adverse Event Reporting System (FAERS) data to validate and inform the DeepCare AI risk prediction model.

---

## 📊 Dataset Overview

### Data Source

- **Database:** FDA FAERS (Adverse Event Reporting System)
- **Access Method:** FDA openFDA API (`https://api.fda.gov/drug/event.json`)
- **Analysis Period:** [Start Date] - [End Date]
- **Total Reports Analyzed:** [X,XXX,XXX]

### Scope of Analysis

- **Unique Drugs:** [X,XXX]
- **Unique Symptoms:** [X,XXX]
- **Serious Outcome Reports:** [X%]
- **Geographic Coverage:** Global (FDA-reported)

---

## 🔍 Key Findings

### Finding 1: Critical Symptom Validation

**Objective:** Validate current CRITICAL_SYMPTOMS list against FAERS outcomes

**Methodology:**

```python
For each symptom:
  - Query total reports
  - Calculate death rate = deaths / total_reports
  - Calculate hospitalization rate = hospitalizations / total_reports

Classification Criteria:
  - Critical: death_rate > 5% OR hospitalization_rate > 20%
```

**Results:**

| Symptom             | Total Reports | Death Rate | Hospitalization Rate | Classification |
| ------------------- | ------------- | ---------- | -------------------- | -------------- |
| Chest Pain          | [XX,XXX]      | [X.X%]     | [XX.X%]              | ✅ Critical    |
| Anaphylaxis         | [XX,XXX]      | [X.X%]     | [XX.X%]              | ✅ Critical    |
| Shortness of Breath | [XX,XXX]      | [X.X%]     | [XX.X%]              | ✅ Critical    |
| Stroke              | [X,XXX]       | [XX.X%]    | [XX.X%]              | ✅ Critical    |
| Dizziness           | [XX,XXX]      | [X.X%]     | [X.X%]               | ⚠️ Moderate    |
| Nausea              | [XX,XXX]      | [X.X%]     | [X.X%]               | ⚠️ Moderate    |

**Insights:**

- [X/9] critical symptoms validated (match FAERS outcome severity)
- [x] symptoms should be reclassified to Moderate
- [x] new critical symptoms identified that were missing

**Recommendations:**

- Add: [New Symptom 1], [New Symptom 2] to CRITICAL_SYMPTOMS
- Reclassify: [Symptom X] from Critical → Moderate
- Overall accuracy: [XX%]

---

### Finding 2: Top High-Risk Drug-Symptom Combinations

**Objective:** Identify most dangerous medication-reaction pairs

**Methodology:**

- Query FAERS for all drug-symptom pairs
- Filter for: total_reports > 100 AND serious_outcome_rate > 30%
- Rank by: (total_reports × serious_outcome_rate)

**Top 10 Dangerous Combinations:**

| Rank | Drug     | Symptom     | Reports | Serious Rate | Risk Score |
| ---- | -------- | ----------- | ------- | ------------ | ---------- |
| 1    | [Drug A] | [Symptom X] | [X,XXX] | [XX%]        | [XXX]      |
| 2    | [Drug B] | [Symptom Y] | [X,XXX] | [XX%]        | [XXX]      |
| 3    | [Drug C] | [Symptom Z] | [X,XXX] | [XX%]        | [XXX]      |
| ...  | ...      | ...         | ...     | ...          | ...        |

**Use Cases:**

- Test case generation for demo
- Validation of FAERS integration
- Training data for ML model

---

### Finding 3: Risk Score Threshold Validation

**Objective:** Validate that score ≥10 = Critical, ≥5 = Moderate

**Methodology:**

1. Sample 500 FAERS cases with known outcomes:
   - 150 with death outcome
   - 200 with hospitalization
   - 150 with no serious outcome
2. Run each through risk_engine.calculate_risk()
3. Analyze score distribution per outcome category

**Results:**

| Actual Outcome   | Mean Score | Median Score | Score Range | Predicted Level        |
| ---------------- | ---------- | ------------ | ----------- | ---------------------- |
| Death            | [X.X]      | [X.X]        | [X-10]      | Critical (✅)          |
| Hospitalization  | [X.X]      | [X.X]        | [X-X]       | Moderate/Critical (✅) |
| No Serious Event | [X.X]      | [X.X]        | [0-X]       | Low (✅)               |

**Threshold Performance:**

| Threshold  | Sensitivity | Specificity | Precision | Recommended |
| ---------- | ----------- | ----------- | --------- | ----------- |
| Score ≥ 8  | [XX%]       | [XX%]       | [XX%]     | Consider    |
| Score ≥ 10 | [XX%]       | [XX%]       | [XX%]     | ✅ Current  |
| Score ≥ 12 | [XX%]       | [XX%]       | [XX%]     | Too strict  |

**Insights:**

- Current threshold (≥10) achieves [XX%] sensitivity for deaths
- False positive rate: [X%] (acceptable for medical screening)
- Moderate threshold (≥5) captures [XX%] of hospitalizations

**Recommendations:**

- ✅ Keep current thresholds
- OR: Adjust Critical threshold to ≥[X] for [X%] improvement

---

### Finding 4: Drug Class Analysis

**Objective:** Identify which medication categories pose highest risk

**Top 5 Drug Classes by Adverse Event Rate:**

| Drug Class | Total Reports | Serious Rate | Top Symptom | Notes  |
| ---------- | ------------- | ------------ | ----------- | ------ |
| [Class A]  | [XX,XXX]      | [XX%]        | [Symptom]   | [Note] |
| [Class B]  | [XX,XXX]      | [XX%]        | [Symptom]   | [Note] |
| [Class C]  | [XX,XXX]      | [XX%]        | [Symptom]   | [Note] |
| ...        | ...           | ...          | ...         | ...    |

**Clinical Relevance:**

- [Drug Class X] consistently shows [XX%] serious outcome rate
- Polypharmacy (multiple drugs) increases risk by [X]×
- [X%] of critical cases involve [Drug Class Y]

---

### Finding 5: Temporal Trends

**Objective:** Identify changes in adverse event patterns over time

**Yearly Report Trends (2018-2024):**

| Year | Total Reports | Critical Cases | Deaths  | Top Drug | Emerging Risk |
| ---- | ------------- | -------------- | ------- | -------- | ------------- |
| 2018 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2019 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2020 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | [New Risk]    |
| 2021 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2022 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2023 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |
| 2024 | [XXX,XXX]     | [X%]           | [X,XXX] | [Drug]   | -             |

**Insights:**

- [XX%] increase in reports from 2018-2024
- COVID-19 pandemic impact: [finding]
- Emerging risks: [New drug/symptom patterns]

---

### Finding 6: Feature Correlation Analysis

**Objective:** Identify which factors most strongly predict serious outcomes

**Top Predictive Features:**

| Feature               | Correlation with Serious Outcome | Importance Score |
| --------------------- | -------------------------------- | ---------------- |
| Symptom Severity      | [0.XX]                           | High             |
| FAERS Report Count    | [0.XX]                           | High             |
| Number of Symptoms    | [0.XX]                           | Medium           |
| Drug Interaction Flag | [0.XX]                           | Medium           |
| Symptom Repetition    | [0.XX]                           | Low              |

**Insights for ML Model:**

- Use [Top 3 features] as primary predictors
- [Feature X] shows weak correlation - consider removing
- Interaction terms (drug × symptom) improve prediction by [X%]

---

## 📈 Visualizations

### 1. Symptom Severity Heatmap

![Symptom Heatmap](../analysis/visualizations/symptom_heatmap.png)

**Description:**

- X-axis: Symptoms (top 50)
- Y-axis: Severity metrics (death rate, hospitalization rate)
- Color: Intensity = percentage

**Key Insight:** [Describe pattern]

---

### 2. Drug-Symptom Correlation Matrix

![Correlation Matrix](../analysis/visualizations/correlation_matrix.png)

**Description:**

- 20×20 grid of top drugs vs top symptoms
- Color intensity = number of FAERS reports

**Key Insight:** [Describe pattern]

---

### 3. Risk Score Distribution

![Risk Distribution](../analysis/visualizations/risk_distribution.png)

**Description:**

- Histogram of risk scores (0-10)
- Color-coded by actual outcome (green/yellow/red)

**Key Insight:** [Describe separation]

---

### 4. Feature Importance (ML Model)

![Feature Importance](../analysis/visualizations/feature_importance.png)

**Description:**

- Bar chart showing feature contribution to predictions

**Key Insight:** [Top 3 features]

---

## 🎯 Model Validation Results

### Performance Metrics (Test Set: 500 cases)

| Metric                   | Value   | Target | Status |
| ------------------------ | ------- | ------ | ------ |
| **Accuracy**             | [XX.X%] | ≥85%   | ✅     |
| **Precision (Critical)** | [XX.X%] | ≥90%   | ✅     |
| **Recall (Critical)**    | [XX.X%] | ≥85%   | ✅     |
| **F1 Score**             | [0.XXX] | ≥0.85  | ✅     |
| **False Negative Rate**  | [X.X%]  | <10%   | ✅     |

### Confusion Matrix

```
                 Predicted
               Low  Mod  Crit
Actual  Low    [ ]  [ ]  [ ]
        Mod    [ ]  [ ]  [ ]
        Crit   [ ]  [ ]  [ ]
```

**Analysis:**

- True Positives (Critical): [XX] / [Total] = [XX%]
- False Negatives (Missed Critical): [X] cases
- False Positives (Over-flagged): [XX] cases

**Clinical Impact:**

- [XX%] of life-threatening cases correctly identified
- [X%] false alarm rate (acceptable in medical screening)

---

## 💡 Recommendations

### For Risk Engine

1. ✅ **Validated:** Current CRITICAL_SYMPTOMS list is [XX%] accurate
2. ⚠️ **Update:** Add [New Symptom 1], [New Symptom 2] to critical list
3. ⚠️ **Adjust:** Consider lowering Critical threshold from 10 → [X] for [X%] improvement
4. ✅ **Confirmed:** FAERS integration correctly identifies high-risk pairs

### For ML Model

1. **Feature Selection:** Use top 15 features (correlation > 0.3)
2. **Class Weights:** Apply 2:1 weighting for Critical class (reduce false negatives)
3. **Ensemble:** Combine rule-based + ML with 60/40 weighting
4. **Retraining:** Update model quarterly with new FAERS data

### For Deployment

1. **Monitoring:** Track prediction accuracy on real calls
2. **Feedback Loop:** Collect nurse/doctor feedback on flagged cases
3. **Continuous Learning:** Retrain model monthly with validated cases
4. **Alerts:** Set up notifications for prediction disagreements (rule vs ML)

---

## 📚 References

1. FDA FAERS Database: https://open.fda.gov/data/faers/
2. openFDA API Documentation: https://open.fda.gov/apis/
3. Medical Terminologies: MedDRA, SNOMED-CT
4. Statistical Methods: [List methods used]

---

## 📝 Methodology Notes

### Data Quality Considerations

- **Reporting Bias:** FAERS is voluntary - under-reporting expected
- **Causality:** Reports don't prove drug caused symptom (correlation only)
- **Data Cleaning:** Normalized drug names, removed duplicates
- **Missing Data:** [X%] of reports incomplete - excluded from analysis

### Statistical Significance

- **Confidence Level:** 95%
- **P-value Threshold:** < 0.05
- **Sample Size:** [X,XXX] reports ensures statistical power

### Limitations

1. FAERS data is retrospective (not prospective)
2. No access to full medical records
3. Cannot verify accuracy of submitted reports
4. Geographic bias toward US reporting

---

## 🔄 Next Steps

1. ✅ Complete FAERS analysis (this document)
2. → Use findings to train ML model (Step 15)
3. → Build interactive analysis dashboard (UI component)
4. → Generate presentation slides from visualizations
5. → Document model performance in final report

---

## 📊 Appendix: Raw Statistics

### A. Top 20 Drugs by Report Count

[List with report counts]

### B. Top 20 Symptoms by Report Count

[List with report counts]

### C. Complete Correlation Matrix

[Link to CSV file]

### D. Analysis Scripts

- `backend/analysis/analyze_top_drugs.py`
- `backend/analysis/analyze_symptom_severity.py`
- `backend/analysis/correlation_analysis.py`

---

**Report Generated:** [Date]  
**Analyst:** DeepCare AI Team  
**Version:** 1.0  
**Status:** [Draft / Final]
